

C Janneke Van Der Woude

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9036593/publications.pdf>

Version: 2024-02-01

141
papers

7,215
citations

61984

43
h-index

62596

80
g-index

142
all docs

142
docs citations

142
times ranked

9797
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 531-538.	1.9	8
2	Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1671-1686.e16.	4.4	15
3	Impact of the Coronavirus Disease Pandemic on Health-Related Quality of Life of Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2849-2856.	2.3	7
4	Rotterdam Transition Test. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2022, 74, 60-67.	1.8	5
5	Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2741-2752.e6.	4.4	18
6	Value-based care pathway for inflammatory bowel disease: a protocol for the multicentre longitudinal non-randomised parallel cluster IBD Value study with baseline period. <i>BMJ Open</i> , 2022, 12, e050539.	1.9	4
7	Indications, Postoperative Management, and Long-term Prognosis of Crohn's Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West. <i>Inflammatory Bowel Diseases</i> , 2022, 28, S16-S24.	1.9	2
8	Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: Review of cases reported to the manufacturer's global safety database. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 477-490.	3.7	11
9	Prevalence of ideal cardiovascular health and its correlates in patients with inflammatory bowel disease, psoriasis and spondyloarthritis. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e314-e318.	1.8	2
10	Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3548-3554.	2.3	8
11	Alterations in Fecal Microbiomes and Serum Metabolomes of Fatigued Patients With Quiescent Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 519-527.e5.	4.4	31
12	Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib: Implications for Cardiovascular Risk and Patient Management. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e25-e25.	1.9	1
13	Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. <i>Gut</i> , 2021, 70, 1266-1274.	12.1	40
14	Decreasing Trends in Intestinal Resection and Re-Resection in Crohn's Disease. <i>Annals of Surgery</i> , 2021, 273, 557-563.	4.2	21
15	Ustekinumab for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1920-1930.	1.3	22
16	Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 234-248.	3.7	47
17	Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 999-1012.	3.7	7
18	Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 1756284821110321.	3.2	12

#	ARTICLE	IF	CITATIONS
19	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 179-187.e6.	4.4	57
20	Long-term Evaluation of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy for Crohn's Disease Perianal Fistulas. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 64-70.	1.3	80
21	Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 309-315.	1.3	31
22	Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1189-1199.	4.7	24
23	Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 129-138.	3.7	87
24	Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 637-646.e11.	4.4	67
25	Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1704-1718.	4.4	19
26	Diagnosis and Outcome of Oesophageal Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 624-629.	1.3	2
27	Ozanimod in Crohn's disease: a promising new player. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 791-792.	8.1	2
28	Autologous Platelet-Rich Stroma in Complex Perianal Fistulas. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 860-861.	1.3	4
29	Intestinal resection rates in Crohn's disease decline across two different epidemiological areas: a consistent observation not merely due to introduction of anti-TNF. <i>Gut</i> , 2020, 69, 1708.1-1709.	12.1	3
30	High Immunogenicity to Influenza Vaccination in Crohn's Disease Patients Treated with Ustekinumab. <i>Vaccines</i> , 2020, 8, 455.	4.4	35
31	Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1489-1500.	2.2	3
32	Limited added value of laboratory monitoring in thiopurine maintenance monotherapy in inflammatory bowel disease patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1353-1364.	3.7	5
33	Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 880-888.	3.7	64
34	Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 123-134.	3.7	92
35	Comment on "Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease". <i>Inflammatory Bowel Diseases</i> , 2019, 25, e59-e59.	1.9	1
36	Effect of Cognitive Behavioral Therapy on Clinical Disease Course in Adolescents and Young Adults With Inflammatory Bowel Disease and Subclinical Anxiety and/or Depression: Results of a Randomized Trial. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1945-1956.	1.9	11

#	ARTICLE	IF	CITATIONS
37	Real-life study of safety of thiopurine-azathiopurine combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 407-415.	3.7	20
38	Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 997-1006.e6.	1.3	86
39	Fecal Matrix Metalloproteinase-9 Measurement for Optimizing Detection of Disease Activity in Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 395-397.	2.2	1
40	A Direct Effect of Sex Hormones on Epithelial Barrier Function in Inflammatory Bowel Disease Models. <i>Cells</i> , 2019, 8, 261.	4.1	51
41	Off-label prescriptions of drugs used for the treatment of Crohn's disease or ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1293-1300.	3.7	6
42	Pregnancy, psychiatry and IBD: multidisciplinary care is crucial. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 265-266.	17.8	3
43	Epithelial endoplasmic reticulum stress orchestrates a protective IgA response. <i>Science</i> , 2019, 363, 993-998.	12.6	51
44	Health Care Transition Outcomes in Inflammatory Bowel Disease: A Multinational Delphi Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1163-1172.	1.3	25
45	Editorial: The Effect of Thiopurines on Offspring. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1-2.	1.3	2
46	Modulatory Effects of Pregnancy on Inflammatory Bowel Disease. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00009.	2.5	24
47	Health-related quality of life in the first 5 years of the children born to mothers with IBD does not differ from children born to healthy mothers. <i>Journal of Psychosomatic Research</i> , 2019, 127, 109840.	2.6	4
48	Cholecystectomy Risk in Crohn's Disease Patients After Ileal Resection: a Long-term Nationwide Cohort Study. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1840-1847.	1.7	3
49	Fatigue in IBD: epidemiology, pathophysiology and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 247-259.	17.8	137
50	Isolated ileal blind loop inflammation after intestinal resection with ileocolonic anastomosis in Crohn's disease: an often neglected endoscopic finding with an unfavorable outcome. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1370-1375.	1.6	6
51	Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1558-1565.	1.9	7
52	Genomic and Expression Analyses Identify a Disease-Modifying Variant for Fibrostenotic Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 582-588.	1.3	16
53	Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease: an International, Cross-disciplinary Consensus. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 408-418.	1.3	102
54	Low dose Naltrexone for induction of remission in inflammatory bowel disease patients. <i>Journal of Translational Medicine</i> , 2018, 16, 55.	4.4	57

#	ARTICLE	IF	CITATIONS
55	Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 939-947.	1.3	41
56	Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 811-818.	3.0	21
57	Correlating Fecal Calprotectin With Hemoglobin Levels Within 1 Sample. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 663-663.	1.9	0
58	TNF- α exerts potent anti-rotavirus effects via the activation of classical NF- κ B pathway. <i>Virus Research</i> , 2018, 253, 28-37.	2.2	36
59	IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes. <i>Nature Communications</i> , 2018, 9, 2427.	12.8	159
60	Defective ATG16L1-mediated removal of IRE1 α drives Crohn's disease-like ileitis. <i>Journal of Experimental Medicine</i> , 2017, 214, 401-422.	8.5	141
61	Prevalence and Phenotype of Concurrent Psoriasis and Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1783-1789.	1.9	59
62	Endoscopy for Inflammatory Bowel Disease During Pregnancy: Only When There Is a Strong Indication. <i>Gastroenterology</i> , 2017, 153, 330-331.	1.3	1
63	Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1232-1241.e1.	4.4	47
64	Sex Is Associated with Adalimumab Side Effects and Drug Survival in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 75-81.	1.9	19
65	Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease. <i>BMJ Open</i> , 2017, 7, e016695.	1.9	33
66	An unexpected cause of terminal ileitis. <i>Gastrointestinal Endoscopy</i> , 2017, 85, 453.	1.0	0
67	3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 135-149.	1.3	558
68	6- α -methylmercaptopurine-induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1183-1190.	2.8	23
69	Analysis of SHIP1 expression and activity in Crohn's disease patients. <i>PLoS ONE</i> , 2017, 12, e0182308.	2.5	14
70	Fatigue in patients with inflammatory bowel disease is associated with distinct differences in immune parameters. <i>Clinical and Experimental Gastroenterology</i> , 2017, Volume 10, 83-90.	2.3	31
71	Increased PTP1B expression and phosphatase activity in colorectal cancer results in a more invasive phenotype and worse patient outcome. <i>Oncotarget</i> , 2016, 7, 21922-21938.	1.8	59
72	Convergent Transcription of Interferon-stimulated Genes by TNF- α and IFN- α Augments Antiviral Activity against HCV and HEV. <i>Scientific Reports</i> , 2016, 6, 25482.	3.3	56

#	ARTICLE	IF	CITATIONS
73	Characteristics of Patients With Hidradenitis Suppurativa and Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 482-483.	4.4	3
74	Preconceptional Counselling of IBD Patients. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 871-872.	1.3	9
75	Exposure to anti-TNF agents in utero: controlling health risks. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 387-388.	17.8	7
76	Safety of Tioguanine During Pregnancy in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 159-165.	1.3	13
77	Preconception Care Reduces Relapse of Inflammatory Bowel Disease During Pregnancy. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1285-1292.e1.	4.4	113
78	Similar Depletion of Protective <i>Faecalibacterium prausnitzii</i> in Psoriasis and Inflammatory Bowel Disease, but not in Hidradenitis Suppurativa. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1067-1075.	1.3	152
79	The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. <i>Gastroenterology</i> , 2016, 150, 734-757.e1.	1.3	373
80	Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up. <i>PLoS ONE</i> , 2016, 11, e0142481.	2.5	89
81	The Role of Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Alpha Agents in Children and Adolescents with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2214-2221.	1.9	16
82	Predicting Endoscopic Disease Activity in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	24
83	Does lower gastrointestinal endoscopy during pregnancy pose a risk for mother and child? â€” a systematic review. <i>BMC Gastroenterology</i> , 2015, 15, 15.	2.0	31
84	Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells Promote Healing of Refractory Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2015, 149, 918-927.e6.	1.3	261
85	Self-reported Disability in Patients with Inflammatory Bowel Disease Largely Determined by Disease Activity and Illness Perceptions. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 369-377.	1.9	45
86	Comparison of Costs and Quality of Life in Ulcerative Colitis Patients with an Ileal Pouch-Anal Anastomosis, Ileostomy and Anti-TNF Therapy. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1016-1023.	1.3	30
87	Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 997-1003.	1.3	25
88	Incidence of Interval Colorectal Cancer Among Inflammatory Bowel Disease Patients Undergoing Regular Colonoscopic Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1656-1661.	4.4	66
89	Low molecular weight protein tyrosine phosphatase (LMWPTP) upregulation mediates malignant potential in colorectal cancer. <i>Oncotarget</i> , 2015, 6, 8300-8312.	1.8	30
90	Linkage between genotype and immunological phenotype in Crohn's disease. <i>Annals of Translational Medicine</i> , 2015, 3, 237.	1.7	1

#	ARTICLE	IF	CITATIONS
91	Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35mg once weekly or placebo, concomitant with calcium and vitamin D supplementation. <i>Gut</i> , 2014, 63, 1424-1430.	12.1	21
92	Suppression of p21 ^{Rac} Signaling and Increased Innate Immunity Mediate Remission in Crohn's Disease. <i>Science Translational Medicine</i> , 2014, 6, 233ra53.	12.4	30
93	Effect of Aging on Healthcare Costs of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 637-645.	1.9	15
94	Drug Therapies for Ulcerative Proctitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2157-2178.	1.9	21
95	Disappointing Durable Remission Rates in Complex Crohn's Disease Fistula. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2022-2028.	1.9	116
96	Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF therapy: results from the COIN study. <i>Gut</i> , 2014, 63, 72-79.	12.1	430
97	Risk factors of work disability in patients with inflammatory bowel disease – A Dutch nationwide web-based survey. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 590-597.	1.3	52
98	Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). <i>Gut</i> , 2014, 63, 292-299.	12.1	195
99	Management of gastrointestinal and liver diseases during pregnancy. <i>Gut</i> , 2014, 63, 1014-1023.	12.1	38
100	Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. <i>Gut</i> , 2014, 63, 451-457.	12.1	128
101	Genomic ATG16L1 risk allele-restricted Paneth cell ER stress in quiescent Crohn's disease. <i>Gut</i> , 2014, 63, 1081-1091.	12.1	111
102	N-ECCO survey results of nursing practice in caring for patients with Crohn's disease or ulcerative colitis in Europe. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1300-1307.	1.3	22
103	Novel developments in Crohn's disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 361.	2.4	0
104	Increased Suppressor of Cytokine Signaling-3 Expression Predicts Mucosal Relapse in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 132-140.	1.9	15
105	Extracorporeal Photopheresis (ECP) in Patients with Steroid-dependent Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 293-300.	1.9	41
106	Effects of Discontinuing Anti-Tumor Necrosis Factor Therapy During Pregnancy on the Course of Inflammatory Bowel Disease and Neonatal Exposure. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 318-321.	4.4	127
107	Do pregnancy-related changes in the microbiome stimulate innate immunity?. <i>Trends in Molecular Medicine</i> , 2013, 19, 454-459.	6.7	35
108	Reply to Drs. Silva and Santana's letter. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e152.	1.3	0

#	ARTICLE	IF	CITATIONS
109	The cell biology of the intestinal epithelium and its relation to inflammatory bowel disease. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 798-806.	2.8	18
110	Peripheral Neutrophil Functions and Cell Signalling in Crohn's Disease. <i>PLoS ONE</i> , 2013, 8, e84521.	2.5	34
111	IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. <i>Carcinogenesis</i> , 2012, 33, 1889-1896.	2.8	108
112	Absence of ABCG2-mediated mucosal detoxification in patients with active inflammatory bowel disease is due to impeded protein folding. <i>Biochemical Journal</i> , 2012, 441, 87-93.	3.7	37
113	CD64 distinguishes macrophages from dendritic cells in the gut and reveals the inducing role of mesenteric lymph node macrophages during colitis. <i>European Journal of Immunology</i> , 2012, 42, 3150-3166.	2.9	430
114	SOCS3 in immune regulation of inflammatory bowel disease and inflammatory bowel disease-related cancer. <i>Cytokine and Growth Factor Reviews</i> , 2012, 23, 127-138.	7.2	50
115	Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 116-131.	1.3	18
116	Disease severity does not affect the interval between IBD diagnosis and the development of CRC: Results from two large, Dutch case series. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 435-440.	1.3	12
117	Recommendations for the treatment of ulcerative colitis with infliximab: A gastroenterology expert group consensus. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 248-258.	1.3	38
118	Single-balloon enteroscopy, magnetic resonance enterography, and abdominal US useful for evaluation of small-bowel disease in children with (suspected) Crohn's disease. <i>Gastrointestinal Endoscopy</i> , 2012, 75, 87-94.	1.0	55
119	STAT1, STAT6 and Adenosine 3',5'-Cyclic Monophosphate (cAMP) Signaling Drive SOCS3 Expression in Inactive Ulcerative Colitis. <i>Molecular Medicine</i> , 2012, 18, 1412-1419.	4.4	24
120	New insights into the role of STAT3 in IBD. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1177-1183.	1.9	41
121	Integrated Models of Care in Managing Inflammatory Bowel Disease: A Discussion. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1582-1587.	1.9	51
122	Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2026-2033.	1.9	118
123	Bone cells from patients with quiescent Crohn's disease show a reduced growth potential and an impeded maturation. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 2424-2431.	2.6	5
124	Small bowel Crohn's disease: MR enteroclysis and capsule endoscopy compared to balloon-assisted enteroscopy. <i>Abdominal Imaging</i> , 2012, 37, 397-403.	2.0	40
125	Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 335-341.	3.7	94
126	Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 152-160.	1.9	63

#	ARTICLE	IF	CITATIONS
127	Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2012, 18, 6967.	3.3	26
128	Solution focused therapy: A promising new tool in the management of fatigue in Crohn's disease patients. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 585-591.	1.3	51
129	Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease. <i>PLoS ONE</i> , 2011, 6, e23745.	2.5	99
130	Impeded protein folding and function in active inflammatory bowel disease. <i>Biochemical Society Transactions</i> , 2011, 39, 1107-1111.	3.4	17
131	Biomarker-based prediction of inflammatory bowel disease-related colorectal cancer: a case-control study. <i>Cellular Oncology (Dordrecht)</i> , 2011, 34, 107-117.	4.4	28
132	Anti-inflammatory actions of phosphatidylinositol. <i>European Journal of Immunology</i> , 2011, 41, 1047-1057.	2.9	25
133	Misclassification of dysplasia in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1108-1116.	1.9	54
134	Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human) Tj ETQq0 0 0 rgBT /Overlock 10 Inflammatory Bowel Diseases, 2010, 16, 1708-1716.	1.9	39
135	Role of defective autophagia and the intestinal flora in Crohn disease. <i>Self/nonself</i> , 2010, 1, 323-327.	2.0	4
136	European evidenced-based consensus on reproduction in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 493-510.	1.3	140
137	A short course of corticosteroids prior to surveillance colonoscopy to decrease mucosal inflammation in inflammatory bowel disease patients: Results from a randomized controlled trial. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 661-668.	1.3	18
138	Inflammatory bowel disease-patients are insufficiently educated about the basic characteristics of their disease and the associated risk of colorectal cancer. <i>Digestive and Liver Disease</i> , 2010, 42, 777-784.	0.9	35
139	Surgery is Indicated for Persistent Enterocutaneous Fistulizing Crohn's Disease. <i>Clinical Medicine Gastroenterology</i> , 2008, 1, CGast.S452.	0.2	0
140	Are we ready for top-down therapy for inflammatory bowel diseases: pro. Expert Review of Gastroenterology and Hepatology, 2007, 1, 243-248.	3.0	6
141	Biologics in Crohn's disease: searching indicators for outcome. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1233-1243.	3.1	4